[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Delta Plus, cause for concern?", "description": "New descendant of the Delta variant,  Delta, predominant, 99.8% of sequenced cases in England\nAs of 11 October 2021\n\nDelta, predominant variant, 99.8% of sequenced cases in England \n\nDelta sublineage newly designated as AY.4.2\n\nThere are also small numbers of new cases of Delta with E484K and Delta with E484Q \n\nhttps://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1025827/Technical_Briefing_25.pdf\n\nhttps://www.theguardian.com/world/2021/oct/19/fears-grow-in-england-over-rise-of-new-covid-delta-variant\n\nhttps://www.thesun.co.uk/health/16463658/new-delta-subvariant-uk-more-infectious/\n\nhttps://www.italy24news.com/News/164491.html\n\nhttps://www.msn.com/en-us/health/medical/delta-ay-sub-variant-which-requires-urgent-research-found-in-these-us-states/ar-AAPFk3S\n\nhttps://www.bbc.co.uk/news/health-58965650\n\nUK genetic sequencing, 6%, now 8% or more\n\nUK, over a million sequences performed so far\n\nOn an increasing trajectory\n\nUS, Denmark, Canada\n\nUS, 3 cases sequenced, no clusters reported\n\nNorth Carolina, California, DC\n\n10 cases in Israel, all from US\n\nUK, 14,247 sequenced as of Monday, October 18th \n\nAY.4.2, Delta Plus, Spike protein change\n\n(AY means it is a delta subtype)\n\n(AY.4 is already 80% in the UK)\n\nMutations - Y145H and A222V\n\nFound in various lineages since the beginning of the pandemic\n\nWill this give the virus additional powers?\n\nVaccine escape?\n\nSlight effect on the binding between antibodies and the virus\n\nNot yet a variant of concern or variant under investigation \n\nWHO, next few days, nu variant\n\nOriginal Delta, classified as VOC, UK May 2021 \n\nJuly 2021 experts identified AY.4.2.\n\nSublineage of Delta, increasing slowly since then\n\nProf Francois Balloux, University College London, Genetics Institute\n\nIt is potentially a marginally more infectious strain.\n\nIt's nothing compared with what we saw with Alpha and Delta, which were something like 50 to 60 percent more transmissible. \n\nSo we are talking about something quite subtle here and that is currently under investigation.\n \nAt this stage I would say wait and see, don't panic. \n\nit is not something absolutely disastrous like we saw previously\n\nDr Jeffrey Barrett, Covid-19 Genomics Initiative, Wellcome Sanger Institute, Cambridge, and Prof Francois Balloux\n\nAY.4.2 could be 10-15% more transmissible than the original Delta variant.\n\nUnlikely to be fuelling current UK increases\n\n(That\u2019s mostly school age and to their parents)", "link": "https://www.youtube.com/watch?v=g-AqBrboooI", "date_published": "2021-10-20 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Comparative immunity update", "description": "High infection rates in UK, going down in US\n\nhttps://www.telegraph.co.uk/news/2021/10/19/people-must-cautious-day-to-day-interactions-covid-cases-climb/\n\nLower functional immunity in our population than most other \nWestern European countries\n\nEarly vaccine roll out\n\nAstraZeneca protects slightly less well than Pfizer against infection and transmission, particularly delta variant\n\nSlightly lower overall vaccination coverage, particularly vaccinating teenagers\n\nFewer social restrictions\n\nHigh rates of testing\n\nUK, ONS\n\n https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights\n\nTwo vaccine doses give similar protection as previous infection \n\nTwo doses of either Pfizer-BioNTech or Oxford-AstraZeneca\n\nProvided a similar level of protection as having had a previous natural infection of coronavirus\n\nDuring delta variant times\n\nVaccination reduced the risk of testing positive, \n\nboth when the alpha variant was dominant in the UK (1 December 2020 to 16 May 2021) \n\nand when the delta variant was dominant (17 May to 14 August 2021)\n\nTwo doses of Pfizer-BioNTech\n\nReduced the risk of testing positive by 73% in the delta period\n\nTwo doses of Oxford-AstraZeneca\n\nReduced the risk of testing positive by 62% in the delta period\n\nTwo vaccination doses, more effective than one at preventing symptomatic infection in both periods. \n\nThree weeks after vaccination\n\nTwo doses always more protective than one\n\n(75% v 58%)\n\nInconsistent with covid symptom study\n\nhttps://covid.joinzoe.com/post/do-i-need-a-covid-vaccine-if-ive-had-covid\n\nTwo doses of the Pfizer\n\n87% protection against infection\n\nTwo doses of the AstraZeneca\n\n71% protection against infection\n\nNatural infection alone\n\nOnly gave 65% protection against catching it again\n\nIsraeli data consistent with ONS but inconsistent with covid symptom study\n\nProtection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel\n https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1.full.pdf\n\nVaccination was highly effective \n\nEstimated efficacy for documented infection of 92\u00b78% \nHospitalization 94\u00b72% \nSevere illness 94\u00b74% \nDeath 93\u00b77% \n\nProtection from prior SARS-CoV-2 infection\n\nEstimated efficacy for documented infection of 94\u00b78% \nHospitalization 94\u00b71% \nSevere illness 96\u00b74%\n\nAll deaths registered in the week to 8 October \n\nCOVID-19 deaths fall in England, Northern Ireland and Scotland\nUp in Wales\n\nTotal UK deaths in the week, 12,490\n\n14.7% above the average in 2015 to 2019\n\n820 involved the coronavirus (COVID-19)\n\n154 fewer than the previous week\n\nDeaths involving COVID-19, 1 in 15 deaths (6.6%).\n\nUK total deaths include non-residents.\n\n1 million people in UK countries had COVID-19 in the latest week\n\n1.63% in England (1 in 60 people)\nOne in 70 people the week before\n\n2.18% in Wales (1 in 45 people)\nOne in 55 people the week before \n\n0.82% in Northern Ireland (1 in 120 people)\nOne in 130 people the week before\n \n1.26% in Scotland (1 in 80 people)\nOne in 60 people the week before\n\nGreg and Peter\nHello John, Just to let you know that one of my posts referring to your video on aspiration has been pulled from LinkedIn.   This is the first time that one of my posts has been pulled and I have put out some pretty controversial posts on other subjects.\n\nFeedback from vaccine manufacturers", "link": "https://www.youtube.com/watch?v=E89taTH86_s", "date_published": "2021-10-19 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]